Common Toxicities

Link and colleagues (13) evaluated the chemotherapy use of 13 managed-care, academic, and community practices for the treatment of breast cancer. The aim of the study was to determine the most common regimens used and the incidence of complications. The primary chemotherapy combinations were CMF and doxorubicin-cyclophosphamide (AC) regimens. Thirty percent of patients had dose intensities of <85%, and 27.6% had dose adjustments secondary to neutropenia. The authors concluded that neutropenia was the primary reason that chemotherapy could not be delivered at the optimal dose intensity.

0 0

Post a comment